For the year ending 2025-12-31, DTM had -$14M decrease in cash & cash equivalents over the period. $441M in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 454 |
| Depreciation and amortization | 258 |
| Stock-based compensation | 26 |
| Amortization of operating lease right-of-use assets | 17 |
| Deferred income taxes | 137 |
| Earnings from equity method investees | 138 |
| Dividends from equity method investees | 138 |
| Loss from financing activities | 0 |
| Accounts receivable, net | 24 |
| Accounts payable | -13 |
| Contract liabilities | 26 |
| Other current and noncurrent assets and liabilities | 14 |
| Net cash and cash equivalents from operating activities | 867 |
| Plant and equipment expenditures | 426 |
| Acquisition accounted for as a business combination (and purchase price adjustment) | -10 |
| Distributions from equity method investees | 49 |
| Contributions to equity method investees | 5 |
| Other investing activities | 0 |
| Net cash and cash equivalents used for investing activities | -372 |
| Issuance of long-term debt, net of discount and issuance costs | 0 |
| Repayment of long-term debt | 0 |
| Borrowings under the revolving credit facility | 330 |
| Repayment of borrowings under the revolving credit facility | 480 |
| Payment of revolving credit facility issuance costs | 0 |
| Issuance of common stock, net of issuance costs | 0 |
| Contributions from noncontrolling interests | 7 |
| Distributions to noncontrolling interests | 17 |
| Dividends paid on common stock | 324 |
| Other financing activities | -25 |
| Net cash and cash equivalents from (used for) financing activities | -509 |
| Net increase (decrease) in cash and cash equivalents | -14 |
| Cash and cash equivalents at beginning of period | 68 |
| Cash and cash equivalents at end of period | 54 |